Food and Drug Administration (FDA) specifically for weight loss
Pre-deal path from analyst models were about $37.5 billion for semaglutide in 2026, off a roughly $33 billion 2025 base
Semaglutide is an FDA-approved medication that has gained attention for its effectiveness in managing weight loss and type 2 diabetes
It has a market cap of $430 billion, but Pot believes it could double as it develops more weight-loss products
Looking at the obesity/mental health connection from the other direction, the most common disorders, including depression, anxiety, and PTSD, can all affect eating behaviors, and many of the lifesaving medications to treat these disorders cause significant weight gain
Standardizing Training for Psoriasis Measures: Effectiveness of an Online Training Video on Psoriasis Area and Severity Index Assessment by Physician and Patient Raters